Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Japan Lifeline CoFRA:L8B -1.73%90 3-Year EBITDA Growth Rate is 11.20% as of Jun. 2026, which is 187% above its 10-year median of 3.90. GuruFocus rates FRA:L8B with a GF Score™ of 90/100 and a GF Value™ of €8.51. The stock has 3 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Japan Lifeline Co ranks better than 53.2% on this metric.
During the past 12 months, Japan Lifeline Co's average EBITDA Per Share Growth Rate was 2.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 17.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Japan Lifeline Co was 95.10% per year. The lowest was -29.90% per year. And the median was 3.90% per year.
Japan Lifeline Co (FRA:L8B) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Japan Lifeline Co 3-Year EBITDA Growth Rate Related Terms
FRA:L8B vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Japan Lifeline Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Lifeline Co 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Japan Lifeline Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Japan Lifeline Co's 3-Year EBITDA Growth Rate falls into.
Japan Lifeline Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.20% mean?
Japan Lifeline Co (FRA:L8B) has a 3-Year EBITDA Growth Rate of 11.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Japan Lifeline Co and its competitors. This is 187% above median its historical median of 3.90. According to the industry distribution chart, Japan Lifeline Co ranks #322 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 46.8%.
Is Japan Lifeline Co's 3-Year EBITDA Growth Rate too high?
Japan Lifeline Co's current 3-Year EBITDA Growth Rate of 11.20% is 187% above median its 10-year median of 3.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Japan Lifeline Co's value of 11.20% is 38.3% above this industry median. Based on the distribution chart, Japan Lifeline Co ranks #322 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Japan Lifeline Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Japan Lifeline Co's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Japan Lifeline Co ranks #322 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Japan Lifeline Co in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Japan Lifeline Co's value of 11.20% is 38.3% above this benchmark. While the company's 10-year median is 3.90 vs. the industry median of 8.10, Japan Lifeline Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Japan Lifeline Co's current 3-Year EBITDA Growth Rate of 11.20% is 38.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Japan Lifeline Co and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Lifeline Co's current 3-Year EBITDA Growth Rate is 11.20%, which is 187% above median its own 10-year median of 3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Lifeline Co stock overvalued right now?
Japan Lifeline Co (FRA:L8B) has a current 3-Year EBITDA Growth Rate of 11.20%. The stock's GF Value™ is €8.51, compared to a current price of €8.50 — trading 0.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.20%, which is 187% above median its 10-year median of 3.90 and 38.3% above the Medical Devices & Instruments industry median of 8.10. Japan Lifeline Co's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Japan Lifeline Co (FRA:L8B), the current 3-Year EBITDA Growth Rate is 11.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Lifeline Co (FRA:L8B) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Lifeline Co stock appears to be undervalued.
The current stock price of €8.50 is trading 0.1% below its estimated GF Value™ of €8.51.
Key valuation signals for FRA:L8B:
3-Year EBITDA Growth Rate: 11.20% (187% above median its 10-year median of 3.90)
GF Value™: €8.51 vs. price of €8.50 (0.1% below fair value)
Industry Position: 38.3% above the Medical Devices & Instruments median (#322 of 688)
No single metric tells the full story. See the FRA:L8B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Lifeline Co Ltd is a medical device company operating in Japan. It is engaged in the trading and manufacturing of medical devices specialized in the cardiovascular field. The company offers medical devices mainly for the treatment of cardiac and vascular diseases. It focuses on providing implantable devices to treat arrhythmias; disposable catheter devices with electrodes for diagnosis and treatment of arrhythmias; prosthetic devices to replace blood vessels and heart valves that lost their functions; and devices for intravascular treatment of cardiac infarction, arterial occlusions of the lower extremities and congenital cardiac diseases.
90GF Score
Get the complete analysis for FRA:L8B
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L8B has been successfully added to your 
